Roche
4 abstracts
Abstract
The pathway alteration load as a pan-cancer determinant of outcome of targeted therapies: Results from the Drug Rediscovery Protocol (DRUP).Org: Department of Molecular Oncology & Immunology, Netherlands Cancer Institute (Netherlands), Hartwig Medical Foundation, Erasmus Medical Cancer Institute, Department of Biometrics,
Abstract
ctDNA mutational profiles in luminal breast cancer with early vs late distant relapse: Geicam/2014-03.Org: Fundación Instituto Valenciano de Oncología (FIVO), GEICAM Spanish Breast Cancer Group, Valencia, Spain, GEICAM Spanish Breast Cancer Group, Barcelona, Spain, Hospital Universitario de Donostia-BioDonostia, Hospital de la Santa Creu i Sant Pau, Hospital Universitario de Canarias,
Abstract
Two-year lung cancer survival between 2000 to 2020: Results from 3 French nationwide cohorts.Org: Service de Pneumologie, Groupe Hospitalier de la Région Mulhouse Sud-Alsace, hôpital Émile-Muller, Mulhouse, France, CHI De Creteil, Créteil, France, HIA SAINTE ANNE, Toulon, France, Hospital Center De La Cote Basque, Bayonne, France, Centre Hospitalier, Le Mans, France,
Abstract
Cancer survival (SURVCANCER BRAZIL): Analysis of 132,621 cases from 19 hospital-based registries in southernmost Brazilian state comparing public and private insurance.Org: Hayde Health, Instituto Tacchini de Pesquisa em Saude (ITPS), Latin American Cooperative Oncology Group (LACOG), Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil, Hospital Israelita Albert Einstein,